Phase I trial of SAGE 689

Trial Profile

Phase I trial of SAGE 689

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs SAGE 689 (Primary)
  • Indications Status epilepticus
  • Focus Adverse reactions
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 15 Dec 2015 According to a Sage Therapeutics media release, this trial is expected to be initiated in the second half of 2016.
    • 05 Nov 2015 According to a media release, SAGE Therapeutics is delaying the initiation of phase I trial of SAGE-689 to respond to requests from the U.S. FDA for additional non-clinical study data unrelated to toxicology.
    • 09 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top